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Clinical resistance to tenofovir disoproxil fumarate (TDF) did not develop in any patient after 8 years of TDF treatment in a phase III clinical trial for treatment-naïve patients with chronic hepatitis B (CHB) \[[@b1-cmh-2017-0045]\]. Potent efficacy and high barrier to resistance of TDF have been established, even in patients who have been previously treated with nucleos(t)ide analogues (NUCs) or have NUC-resistant hepatitis B virus (HBV) variants. We previously reported that TDF-based rescue therapy was effective in patients harboring lamivudine (LAM)-resistant or multidrug-resistant HBV variants \[[@b2-cmh-2017-0045],[@b3-cmh-2017-0045]\]. Moreover, two randomized controlled trials evaluating the efficacy of TDF monotherapy in patients infected with HBV variants resistant to adefovir (ADV) and entecavir (ETV) were conducted, and non-inferior antiviral efficacy compared with TDF plus ETV combination therapy was demonstrated \[[@b4-cmh-2017-0045],[@b5-cmh-2017-0045]\]. On the basis of *in vitro* and *in vivo* data, there was concern that HBV susceptibility to TDF may be reduced in patients with HBV strains with substitutions conferring ADV resistance (rtA181T/V and rtN236T), but TDF has shown antiviral efficacy dispelling such concern. Thus, recently updated international guidelines recommend switching to TDF or tenofovir alafenamide as the first-line treatment option for patients with HBV variants resistant to ETV \[[@b6-cmh-2017-0045],[@b7-cmh-2017-0045]\]. However, no long-term data have been driven from clinical practice to assess the antiviral efficacy of TDF monotherapy in patients with ETV resistance.

In this issue of Clinical and Molecular Hepatology, a Korean real-world study by Jeon, et al. indicates that TDF monotherapy was as effective as TDF plus LAM or ETV combination therapy for the treatment of patients infected with HBV strains resistant to both LAM and ETV \[[@b8-cmh-2017-0045]\]. Seventy-three patients with resistance to LAM and ETV were treated with TDF-based rescue therapy for at least 6 months. During a median TDF-based treatment period of 37 months, 63 of 73 patients (86.3%) achieved virologic response, defined as undetectable HBV DNA by quantitative polymerase chain reaction assay (\<12 IU/mL). Virologic response rates in patients treated with TDF alone (n=12) were comparable to those in patients treated with TDF plus LAM (n=19) and TDF plus ETV (n=42) (88.4%, 94.7%, and 84.2%, respectively, at 24 months; *P*=0.200). On multivariate analysis, lower baseline HBV DNA level was an independent predictive factor of virologic response achieved by TDF-based rescue therapy (hazard ratio \[HR\]=0.723; *P*\<0.001). However, we must consider the possibility of a type II error underlying Jeon, et al. study, which results from a sample size that is not large enough to detect small differences between TDF monotherapy and TDF-based combination therapies. In addition, baseline HBV DNA level, which was the only independent factor predictive of virologic response, differed significantly among the three groups (*P* =0.021). The proportion of HBeAg-positive patients was lower, albeit non-significant (*P* =0.096), in the TDF monotherapy group (66.7%) than in the TDF plus LAM combination therapy group (89.5%) and in the TDF plus ETV combination therapy group (90.5%). Therefore, a real-world study with a larger sample size and/or a sufficiently long-term follow-up is needed to demonstrate the non-inferior efficacy of TDF monotherapy compared to TDF-based combination therapy. To adjust for treatment selection bias, which is an inevitable challenge of retrospective studies, statistical methods (e.g., propensity score analysis) may be adopted. Nevertheless, Jeon, et al. study is worthy of consideration as a real-world study of ETV-resistant CHB patients from Korea and advocates the switching-to TDF monotherapy as recommended by the international guidelines \[[@b6-cmh-2017-0045],[@b7-cmh-2017-0045]\].

Jeon, et al. study did not include ADV-experienced patients or patients with resistance to ADV. As aforementioned, if patients have experienced and failed ADV treatment or if genotypic resistance to ADV has emerged prior to TDF treatment, HBV susceptibility to TDF may be decreased, which may, in turn, attenuate the antiviral activity of TDF. When the virologic response rates after TDF treatment were compared between NUC-experienced and NUC-naïve patients, ADV-experienced patients showed lower virologic response rates compared to NUC-experienced but ADV-naïve patients (68.8% versus 89.1%). Furthermore, previous exposure to ADV was determined to significantly influence virologic response after TDF treatment in multivariate analysis (HR=0.37; *P* =0.003) \[[@b9-cmh-2017-0045]\]. Even though TDF monotherapy was as effective as TDF plus ETV combination therapy in ADV-resistant patients in the previous study, we would need more long-term follow-up data to confirm the antiviral efficacy of TDF against ADV-resistant HBV strains \[[@b5-cmh-2017-0045]\].

We have two therapeutic options for patients harboring HBV variants resistant to ETV---whether to switch to TDF monotherapy or add TDF on ETV. Previous study findings, including those of Jeon, et al. study, have pointed towards TDF monotherapy as an uncontroversial option taking into consideration the lower cost and potential risk of adverse events, as well as the non-inferior efficacy compared to ETV plus TDF combination therapy. However, antiviral resistance to any NUC can emerge, even if ETV or TDF has high barrier to resistance. It is clear that the barrier of tenofovir against resistance is very high, but HBV quasispecies perpetually evolve and acquire drug-resistant strains. The barriers to potent antiviral drugs can eventually collapse if the drug-resistant HBV strains are selected under antiviral pressure during long-term antiviral therapy; therefore, we should be alert and prepared with carefully selected treatment strategies. The most critical adverse event of treatment with any antimicrobial agent is the emergence of drug resistance. It is worth noting that TDF may be an exception to this rule and provide a last line of defense against drug resistance.
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